Johns Hopkins Medicine 公開
[search 0]
もっと

Download the App!

show episodes
 
The mission of the Johns Hopkins Hospital Nursing Research Program is to inspire and engage with nurses to participate in and disseminate the three forms of inquiry: evidence-based practice, quality improvement, and research. The Center for Nursing Inquiry’s purpose is to increase the competence, confidence and capacity of Hopkins nurses to engage in meaningful scholarly activities.
 
Hosted by Bill Curtis and quadruple board certified Dr. Steven Taback, Medicine, We’re Still Practicing sits down with doctors from the world’s most preeminent hospitals for insights into their research, practice, and education. The first in this dedicated series is Johns Hopkins Medicine, with the goal of not only to share the magnificent work being done by these hospitals and doctors, but for them to be able to use it as a high-quality educational tool and platform to share insights and re ...
 
Informative and entertaining stories from the editors of the journal Medicine featuring article highlights, hot topics, and other things on their minds. The journal, published every other month and now in its 90th year, includes scholarly reviews and clinical descriptions of patients from the experience of leading clinicians from around the world in the areas of internal medicine, dermatology, neurology, pediatrics, and psychiatry. The editors, David Hellmann, John Bartlett, Howard Lederman, ...
 
Loading …
show series
 
Imagine you have moderate to severe depression. Would you stop taking your medicines to be part of a research study comparing psilocybin to a traditional antidepressant? That was a requirement for participants in a recently reported study, and Matthew Johnson, a psychedelics researcher at Johns Hopkins, says that’s not all. Johnson: In addition to …
 
Children don’t get severe Covid-19 disease as often as older people do. That assertion underpins decisions to travel with children and otherwise exercise fewer precautions against infection in this population. Yet Covid is not benign for kids. That’s according to Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins. Milstone: It’s…
 
Imagine you have moderate to severe depression. Would you stop taking your medicines to be part of a research study comparing psilocybin to a traditional antidepressant? That was a requirement for participants in a recently reported study, and Matthew Johnson, a psychedelics researcher at Johns Hopkins, says that’s not all. Johnson: In addition to …
 
Imagine you have moderate to severe depression. Would you stop taking your medicines to be part of a research study comparing psilocybin to a traditional antidepressant? That was a requirement for participants in a recently reported study, and Matthew Johnson, a psychedelics researcher at Johns Hopkins, says that’s not all. Johnson: In addition to …
 
Imagine you have moderate to severe depression. Would you stop taking your medicines to be part of a research study comparing psilocybin to a traditional antidepressant? That was a requirement for participants in a recently reported study, and Matthew Johnson, a psychedelics researcher at Johns Hopkins, says that’s not all. Johnson: In addition to …
 
Psilocybin compared favorably with a traditional antidepressant for treating moderate to severe depression, a recent study found. Matthew Johnson, a psychedelics researcher at Johns Hopkins, says an entirely different clinical approach will be required to use psilocybin routinely for depression. Johnson: That’s really for two reasons: the environme…
 
Psilocybin compared favorably with a traditional antidepressant for treating moderate to severe depression, a recent study found. Matthew Johnson, a psychedelics researcher at Johns Hopkins, says an entirely different clinical approach will be required to use psilocybin routinely for depression. Johnson: That’s really for two reasons: the environme…
 
Psilocybin compared favorably with a traditional antidepressant for treating moderate to severe depression, a recent study found. Matthew Johnson, a psychedelics researcher at Johns Hopkins, says an entirely different clinical approach will be required to use psilocybin routinely for depression. Johnson: That’s really for two reasons: the environme…
 
Psilocybin compared favorably with a traditional antidepressant for treating moderate to severe depression, a recent study found. Matthew Johnson, a psychedelics researcher at Johns Hopkins, says an entirely different clinical approach will be required to use psilocybin routinely for depression. Johnson: That’s really for two reasons: the environme…
 
For people with depression, sometimes traditional antidepressant medicines simply don’t work. Now psychedelic medicines may be a new choice, if the results of a study comparing psilocybin to escitalopram, an antidepressant, hold up. Matthew Johnson, a psychedelics researcher at Johns Hopkins, comments. Johnson: Traditional antidepressants help many…
 
For people with depression, sometimes traditional antidepressant medicines simply don’t work. Now psychedelic medicines may be a new choice, if the results of a study comparing psilocybin to escitalopram, an antidepressant, hold up. Matthew Johnson, a psychedelics researcher at Johns Hopkins, comments. Johnson: Traditional antidepressants help many…
 
For people with depression, sometimes traditional antidepressant medicines simply don’t work. Now psychedelic medicines may be a new choice, if the results of a study comparing psilocybin to escitalopram, an antidepressant, hold up. Matthew Johnson, a psychedelics researcher at Johns Hopkins, comments. Johnson: Traditional antidepressants help many…
 
For people with depression, sometimes traditional antidepressant medicines simply don’t work. Now psychedelic medicines may be a new choice, if the results of a study comparing psilocybin to escitalopram, an antidepressant, hold up. Matthew Johnson, a psychedelics researcher at Johns Hopkins, comments. Johnson: Traditional antidepressants help many…
 
Depression can be hard to treat, with even established medicines taking time to be effective and perhaps not helping at all. Now a new study compared the psychedelic drug psilocybin with escitalopram, an established antidepressant, and the results impressed Matthew Johnson, a psychedelics researcher at Johns Hopkins, for the relief of depression. J…
 
Depression can be hard to treat, with even established medicines taking time to be effective and perhaps not helping at all. Now a new study compared the psychedelic drug psilocybin with escitalopram, an established antidepressant, and the results impressed Matthew Johnson, a psychedelics researcher at Johns Hopkins, for the relief of depression. J…
 
Depression can be hard to treat, with even established medicines taking time to be effective and perhaps not helping at all. Now a new study compared the psychedelic drug psilocybin with escitalopram, an established antidepressant, and the results impressed Matthew Johnson, a psychedelics researcher at Johns Hopkins, for the relief of depression. J…
 
Depression can be hard to treat, with even established medicines taking time to be effective and perhaps not helping at all. Now a new study compared the psychedelic drug psilocybin with escitalopram, an established antidepressant, and the results impressed Matthew Johnson, a psychedelics researcher at Johns Hopkins, for the relief of depression. J…
 
Can the psychedelic drug psilocybin be used to treat depression? That possibility was examined in a recent study comparing psilocybin to escitalopram, an established antidepressant, in people with moderate to severe depression. Matthew Johnson, a psychedelics researcher at Johns Hopkins, describes the results. Johnson: I think it’s an extremely pos…
 
Can the psychedelic drug psilocybin be used to treat depression? That possibility was examined in a recent study comparing psilocybin to escitalopram, an established antidepressant, in people with moderate to severe depression. Matthew Johnson, a psychedelics researcher at Johns Hopkins, describes the results. Johnson: I think it’s an extremely pos…
 
Can the psychedelic drug psilocybin be used to treat depression? That possibility was examined in a recent study comparing psilocybin to escitalopram, an established antidepressant, in people with moderate to severe depression. Matthew Johnson, a psychedelics researcher at Johns Hopkins, describes the results. Johnson: I think it’s an extremely pos…
 
Can the psychedelic drug psilocybin be used to treat depression? That possibility was examined in a recent study comparing psilocybin to escitalopram, an established antidepressant, in people with moderate to severe depression. Matthew Johnson, a psychedelics researcher at Johns Hopkins, describes the results. Johnson: I think it’s an extremely pos…
 
In our final installment for our Johns Hopkins series, hosts Dr. Steven Taback and Bill Curtis are joined by founder of the field and Johns Hopkins Director of Neuroplastic Facial Reconstruction, Dr. Chad Gordon. In this episode, Dr. Gordon illuminates the groundbreaking developments in Smart Cranial Implants, and shares his passion for the importa…
 
Children don’t get severe Covid-19 disease as often as older people do. That assertion underpins decisions to travel with children and otherwise exercise fewer precautions against infection in this population. Yet Covid is not benign for kids. That’s according to Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins. Milstone: It’s…
 
Children don’t get severe Covid-19 disease as often as older people do. That assertion underpins decisions to travel with children and otherwise exercise fewer precautions against infection in this population. Yet Covid is not benign for kids. That’s according to Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins. Milstone: It’s…
 
Children don’t get severe Covid-19 disease as often as older people do. That assertion underpins decisions to travel with children and otherwise exercise fewer precautions against infection in this population. Yet Covid is not benign for kids. That’s according to Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins. Milstone: It’s…
 
Children don’t get severe Covid-19 disease as often as older people do. That assertion underpins decisions to travel with children and otherwise exercise fewer precautions against infection in this population. Yet Covid is not benign for kids. That’s according to Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins. Milstone: It’s…
 
As the Covid pandemic rages on, more younger people are becoming infected, and more variants are being reported. Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins, is concerned that children might begin experiencing infections more commonly as a result. Milstone: We’ll learn more about whether kids will be disproportionately af…
 
As the Covid pandemic rages on, more younger people are becoming infected, and more variants are being reported. Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins, is concerned that children might begin experiencing infections more commonly as a result. Milstone: We’ll learn more about whether kids will be disproportionately af…
 
As the Covid pandemic rages on, more younger people are becoming infected, and more variants are being reported. Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins, is concerned that children might begin experiencing infections more commonly as a result. Milstone: We’ll learn more about whether kids will be disproportionately af…
 
As the Covid pandemic rages on, more younger people are becoming infected, and more variants are being reported. Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins, is concerned that children might begin experiencing infections more commonly as a result. Milstone: We’ll learn more about whether kids will be disproportionately af…
 
As the Covid pandemic rages on, more younger people are becoming infected, and more variants are being reported. Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins, is concerned that children might begin experiencing infections more commonly as a result. Milstone: We’ll learn more about whether kids will be disproportionately af…
 
Multisystem inflammatory syndrome in children, abbreviated MIS-C, appears to be on the rise in the US. Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins, says the syndrome may sneak up in unpredictable ways. Milstone: We have a lot of people come in and they don’t understand why their kid is sick. And we […]…
 
Multisystem inflammatory syndrome in children, abbreviated MIS-C, appears to be on the rise in the US. Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins, says the syndrome may sneak up in unpredictable ways. Milstone: We have a lot of people come in and they don’t understand why their kid is sick. And we […]…
 
Multisystem inflammatory syndrome in children, abbreviated MIS-C, appears to be on the rise in the US. Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins, says the syndrome may sneak up in unpredictable ways. Milstone: We have a lot of people come in and they don’t understand why their kid is sick. And we […]…
 
Multisystem inflammatory syndrome in children, abbreviated MIS-C, appears to be on the rise in the US. Aaron Milstone, a pediatric infectious disease expert at Johns Hopkins, says the syndrome may sneak up in unpredictable ways. Milstone: We have a lot of people come in and they don’t understand why their kid is sick. And we […]…
 
Loading …

クイックリファレンスガイド

Google login Twitter login Classic login